FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901433867> ?p ?o ?g. }

• W2901433867 endingPage "695" @default.
• W2901433867 startingPage "685" @default.
• W2901433867 abstract "Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Altered lymphocyte cell counts and a potential association with increased infection rates have been reported in RA patients treated with JAK inhibitors. This analysis was undertaken to evaluate the short-, mid-, and long-term effects of tofacitinib on lymphocytes and infection rates in patients with RA.In this post hoc analysis, absolute lymphocyte counts (ALCs) were obtained from phase III studies (12-24 months; n = 717-958) and phase I/II/III/long-term extension studies of tofacitinib (≤117 months) (All RA population; n = 7,061); lymphocyte subset counts (LSCs) were from phase II studies (1.5-6 months' exposure; n = 236-486), an ORAL Sequel vaccine substudy (~22 months; n = 198), and an ORAL Sequel lymphocyte substudy (~50 months; n = 55-1,035) of tofacitinib. The reversibility of ALC/LSC changes was evaluated. The relationship of ALC and LSC to infections was analyzed in the All RA population. The value of monitoring ALC alone was assessed by examining correlations between ALCs and LSCs.Tofacitinib treatment resulted in an initial increase in ALC versus pretreatment baseline, which gradually declined to steady state by ~48 months. CD4+ and CD8+ T cell counts decreased over long-term treatment, and ALC and LSC changes were reversible upon treatment cessation. Patients with ALCs of <500 cells/mm3 had an increased risk of serious infections. There was no strong association between CD4+ T cell, CD8+ T cell, B cell, or natural killer cell counts and serious infection incidence rates. ALC and CD4+ or CD8+ T cell counts correlated well (R = 0.65-0.86).Our findings indicate that monitoring of ALC alone appears to be adequate to assess infection risk in tofacitinib-treated patients with RA." @default.
• W2901433867 created "2018-11-29" @default.
• W2901433867 creator A5007829132 @default.
• W2901433867 creator A5023265561 @default.
• W2901433867 creator A5023285300 @default.
• W2901433867 creator A5024958150 @default.
• W2901433867 creator A5025867925 @default.
• W2901433867 creator A5027752564 @default.
• W2901433867 creator A5028283706 @default.
• W2901433867 creator A5037386752 @default.
• W2901433867 creator A5053704561 @default.
• W2901433867 creator A5060809503 @default.
• W2901433867 creator A5079584836 @default.
• W2901433867 creator A5083583562 @default.
• W2901433867 creator A5089961811 @default.
• W2901433867 date "2019-04-02" @default.
• W2901433867 modified "2023-10-16" @default.
• W2901433867 title "Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis" @default.
• W2901433867 cites W1561070512 @default.
• W2901433867 cites W1970276280 @default.
• W2901433867 cites W1974321634 @default.
• W2901433867 cites W1990105300 @default.
• W2901433867 cites W1994696611 @default.
• W2901433867 cites W2014330392 @default.
• W2901433867 cites W2015278246 @default.
• W2901433867 cites W2035320881 @default.
• W2901433867 cites W2038992287 @default.
• W2901433867 cites W2046744512 @default.
• W2901433867 cites W2051371256 @default.
• W2901433867 cites W2062515891 @default.
• W2901433867 cites W2069302785 @default.
• W2901433867 cites W2069341878 @default.
• W2901433867 cites W2086121828 @default.
• W2901433867 cites W2097302763 @default.
• W2901433867 cites W2101217991 @default.
• W2901433867 cites W2113485611 @default.
• W2901433867 cites W2119080021 @default.
• W2901433867 cites W2121219094 @default.
• W2901433867 cites W2129948300 @default.
• W2901433867 cites W2138609584 @default.
• W2901433867 cites W2149447280 @default.
• W2901433867 cites W2152348310 @default.
• W2901433867 cites W2153414586 @default.
• W2901433867 cites W2164858045 @default.
• W2901433867 cites W2218477436 @default.
• W2901433867 cites W2265836205 @default.
• W2901433867 cites W2413887177 @default.
• W2901433867 cites W2559407770 @default.
• W2901433867 cites W2584430503 @default.
• W2901433867 cites W2749941863 @default.
• W2901433867 cites W2766388669 @default.
• W2901433867 cites W4250786926 @default.
• W2901433867 doi "https://doi.org/10.1002/art.40780" @default.
• W2901433867 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6593802" @default.
• W2901433867 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30427585" @default.
• W2901433867 hasPublicationYear "2019" @default.
• W2901433867 type Work @default.
• W2901433867 sameAs 2901433867 @default.
• W2901433867 citedByCount "31" @default.
• W2901433867 countsByYear W29014338672019 @default.
• W2901433867 countsByYear W29014338672020 @default.
• W2901433867 countsByYear W29014338672021 @default.
• W2901433867 countsByYear W29014338672022 @default.
• W2901433867 countsByYear W29014338672023 @default.
• W2901433867 crossrefType "journal-article" @default.
• W2901433867 hasAuthorship W2901433867A5007829132 @default.
• W2901433867 hasAuthorship W2901433867A5023265561 @default.
• W2901433867 hasAuthorship W2901433867A5023285300 @default.
• W2901433867 hasAuthorship W2901433867A5024958150 @default.
• W2901433867 hasAuthorship W2901433867A5025867925 @default.
• W2901433867 hasAuthorship W2901433867A5027752564 @default.
• W2901433867 hasAuthorship W2901433867A5028283706 @default.
• W2901433867 hasAuthorship W2901433867A5037386752 @default.
• W2901433867 hasAuthorship W2901433867A5053704561 @default.
• W2901433867 hasAuthorship W2901433867A5060809503 @default.
• W2901433867 hasAuthorship W2901433867A5079584836 @default.
• W2901433867 hasAuthorship W2901433867A5083583562 @default.
• W2901433867 hasAuthorship W2901433867A5089961811 @default.
• W2901433867 hasBestOaLocation W29014338671 @default.
• W2901433867 hasConcept C126322002 @default.
• W2901433867 hasConcept C167672396 @default.
• W2901433867 hasConcept C203014093 @default.
• W2901433867 hasConcept C2777077863 @default.
• W2901433867 hasConcept C2777575956 @default.
• W2901433867 hasConcept C2777761686 @default.
• W2901433867 hasConcept C2778886723 @default.
• W2901433867 hasConcept C2908647359 @default.
• W2901433867 hasConcept C71924100 @default.
• W2901433867 hasConcept C8891405 @default.
• W2901433867 hasConcept C90924648 @default.
• W2901433867 hasConcept C99454951 @default.
• W2901433867 hasConceptScore W2901433867C126322002 @default.
• W2901433867 hasConceptScore W2901433867C167672396 @default.
• W2901433867 hasConceptScore W2901433867C203014093 @default.
• W2901433867 hasConceptScore W2901433867C2777077863 @default.
• W2901433867 hasConceptScore W2901433867C2777575956 @default.
• W2901433867 hasConceptScore W2901433867C2777761686 @default.
• W2901433867 hasConceptScore W2901433867C2778886723 @default.

• next